Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects

Aims HMG‐CoA reductase inhibitors (statins) have been demonstrated to have in vitro vascular effects. The aim of this study was to determine whether statins actually have in vivo vascular effects independent of their cholesterol‐lowering effect. Methods We investigated the effect of a single dose of...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2002-10, Vol.54 (4), p.395-399
Main Authors: Omori, Hisako, Nagashima, Hirotaka, Tsurumi, Yukio, Takagi, Atsushi, Ishizuka, Naoko, Hagiwara, Nobuhisa, Kawana, Masatoshi, Kasanuki, Hiroshi
Format: Article
Language:English
Subjects:
Adult
Analysis of Variance
Biological and medical sciences
Blood Flow Velocity - drug effects
Brachial Artery - drug effects
Double-Blind Method
endothelial function
General and cellular metabolism. Vitamins
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
lipid‐lowering therapy
Male
Medical sciences
Pharmacodynamics
Pharmacology. Drug treatments
pleiotropic effect
Pyridines - administration & dosage
Pyridines - pharmacology
statin
ultrasound
Vasodilation - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims HMG‐CoA reductase inhibitors (statins) have been demonstrated to have in vitro vascular effects. The aim of this study was to determine whether statins actually have in vivo vascular effects independent of their cholesterol‐lowering effect. Methods We investigated the effect of a single dose of cerivastatin on vascular endothelial function by measuring flow‐mediated dilatation of the brachial artery on ultrasound in 30 healthy volunteers with normal serum cholesterol concentrations. They were randomized to either placebo group (n = 15) or cerivastatin group (n = 15), and flow‐mediated dilatation and endothelium‐dependent dilatation were evaluated at before and 1 h, 3 h, 6 h, and 12 h after administration of placebo or cerivastatin. Results There were no differences in total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, malondialdehyde‐LDL, and high‐sensitivity C‐reactive protein before and after administration of placebo or cerivastatin. Cerivastatin significantly increased flow‐mediated dilatation at 3 h (P 
ISSN:0306-5251
1365-2125
DOI:10.1046/j.1365-2125.2002.01677.x